Hilab
Hilab is a Brazilian health technology company that develops a cloud-based, AI-powered point-of-care diagnostic platform with four proprietary portable devices (Lens, Flow, Volt, Molecular), covering ~85% of most requested medical tests and serving hospitals, laboratories, clinics, pharmacies, occupational health programs, and public health systems in Brazil.
- Company typePrivate
- Founded2004
- HeadquartersCuritiba, Brazil
- Headcount101–250
- GTM typeB2B
- OfferingHardware or Manufacturing
What Hilab does
Hilab is a Brazilian health technology company headquartered in Curitiba that builds a cloud-based point-of-care diagnostic platform paired with a portfolio of four proprietary portable devices: Hilab Lens (digital microscopy for complete blood counts in up to 25 minutes), Hilab Flow (multi-methodology device covering immunochromatography, fluorescence, and colorimetry with the largest point-of-care portfolio on the market), Hilab Volt (electrochemistry results in up to 8 minutes), and Hilab Molecular (RT-PCR-analogous molecular biology in up to 1 hour). Together the devices cover approximately 85% of the most requested medical tests, and results are processed via an AI-powered cloud platform and delivered to physicians, managers, patients, and specialists through dedicated portal personas.
The company operates across six primary use-case segments: public health (real-time epidemiological surveillance), occupational health (PCMSO workplace exams), laboratories and hospitals (operational cost reduction), clinics and medical offices (faster consultations), retail pharmacies (turnkey laboratory-in-pharmacy services), and independent distributors. Distribution combines direct enterprise sales, a pharmacy channel network, occupational health providers, and recruited distributors. Customers include Renault, which uses the platform in occupational health programs.
Hilab's business model blends hardware sales (the four devices), per-test usage revenue on the cloud platform, and recurring enterprise/institutional contracts. The company holds four ANVISA device registrations, ISO 13485 and ISO 9001 certifications, and is compliant with RDC 786/2023. It has raised approximately $27.8 million in disclosed equity funding since 2018 across multiple rounds (MONASHEES, Qualcomm Ventures, Endeavor Catalyst, Peninsula, Bossa Invest, Google for Startups, and most recently eB Capital, Rise Ventures, and Positivo Tecnologia in 2023), won three consecutive iF Design Awards including a 2022 Gold, and has peer-reviewed clinical validation published in Nature Scientific Reports. The company is now expanding beyond Brazil, having won the Macau Government innovation and entrepreneurship competition in 2025 to pursue the Chinese market.
Hilab firmographics
Firmographics- Name
- Hilab
- Legal name
- Hilab Ltda.
- Website
- https://fazumhilab.com.br
- Company type
- Private
- Founded year
- 2004
- Operating status
- Operating
- Headcount range
- 101–250 employees
- Short description
- Hilab is a Brazilian health technology company that develops a cloud-based, AI-powered point-of-care diagnostic platform with four proprietary portable devices (Lens, Flow, Volt, Molecular), covering ~85% of most requested medical tests and serving hospitals, laboratories, clinics, pharmacies, occupational health programs, and public health systems in Brazil.
- Ownership category
- akta.pro rank
Hilab industry classification
Industry- Product category
- Point-of-Care Diagnostic Devices
- NAICS
- Navigational, Measuring, Electromedical, and Control Instruments Manufacturing (3345), Medical and Diagnostic Laboratories (6215)
- SIC
- Surgical & Medical Instruments & Apparatus (3841), Laboratory Analytical Instruments (3826)
- akta.pro primary industry
- AI Orchestration & Imaging Analytics Platforms (Model Management/Triage) (HLACALAG)
- akta.pro secondary industry
- Imaging & Diagnostic Interoperability (DICOM exchange, image sharing, VNA connectivity) (HLACABAM)
Keywords
Where Hilab is headquartered
LocationHeadquarters
- HQ city
- Curitiba
- HQ country
- Brazil
- HQ region
- Latin America
Offices2 records
Markets served
Hilab business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Supply Chain, Marketing or Sales, Infrastructure
Revenue model
- Point-of-Care Diagnostic Devices: Hilab sells portable diagnostic devices (Hilab Lens, Flow, Volt, Molecular) to healthcare providers, laboratories, pharmacies, and occupational health programs. Devices are sold as capital equipment or as part of integrated solution packages.
- Diagnostic Testing Services (Per-Test): The company operates a per-test revenue model through its point-of-care platform, processing samples and delivering results. The platform covers 85% of the most requested medical tests, with a complete test portfolio across its multi-device ecosystem.
- Enterprise and Institutional Solutions: Hilab sells integrated diagnostic solutions to large laboratories, hospitals, occupational health programs, and public health systems, with the stated goal of expanding negotiations with major laboratory and enterprise clients.
Go-to-market motion2 records
Distribution channels5 records
Marketing channels7 records
Hilab product offering
Product offeringCore offering
Hilab develops and manufactures ultra-compact point-of-care diagnostic devices (Hilab Lens, Flow, Volt, Molecular) that function as mini connected laboratories, paired with a cloud-based AI diagnostic platform that processes health data and delivers results in real time. The portfolio covers approximately 85% of the most requested medical examinations and is sold primarily to healthcare providers, laboratories, hospitals, pharmacies, occupational health programs, and public health systems in Brazil.
Product overview
Hilab develops a cloud-based point-of-care testing platform powered by AI, offering rapid, accessible diagnostic technology. The portfolio consists of four distinct portable diagnostic devices: Hilab Lens (digital microscopy for complete blood counts in 25 minutes), Hilab Flow (multi-methodology device supporting immunochromatography, fluorescence, and colorimetry with the largest portfolio), Hilab Volt (electrochemistry results in 8 minutes), and Hilab Molecular (molecular biology with RT-PCR analogous methodology in 1 hour). Together these devices cover approximately 85% of the most requested medical examinations, serving public health, occupational medicine, laboratories, hospitals, clinics, and pharmacies.
Differentiator
Problem solved
Functional benefit
Brands
- Hilab Lens: The smallest point-of-care blood count device in the world, made by digital microscopy with results in up to 25 minutes.
- Hilab Flow
- Hilab Volt
- Hilab Molecular
Products and services
- Hilab Lens The smallest point-of-care complete blood count (hemograma) device in the world, using digital microscopy and AI-powered image analysis to deliver results in up to 25 minutes. Intended for healthcare providers, laboratories, hospitals, clinics, pharmacies, occupational health programs, and public health systems. ANVISA registration 80583710047.
- Hilab Flow Multi-methodology point-of-care diagnostic device supporting immunochromatography, fluorescence, and colorimetry testing, marketed as having the largest point-of-care portfolio in the market. Intended for healthcare providers, laboratories, hospitals, clinics, pharmacies, and occupational health programs. ANVISA registration 80583710007.
- Hilab Volt The smallest electrochemistry point-of-care device on the market, delivering diagnostic results in up to 8 minutes. Intended for healthcare providers, laboratories, hospitals, clinics, pharmacies, occupational health programs, and public health systems. ANVISA registration 80583710019.
- Hilab Molecular The smallest molecular biology point-of-care device, using methodology analogous to RT-PCR with results delivered in up to 1 hour. Intended for healthcare providers, laboratories, hospitals, clinics, occupational health programs, and public health systems. ANVISA registration 80583710015.
Quantifiable outcome
- Hilab Lens delivers CBC results in up to 25 minutes — compared to hours or days for traditional laboratory processing
- +4 more outcomes
Companies that use Hilab
Customer profileNamed customers5 records
Segments6 records
Ideal customer profiles6 records
Hilab technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability4 records
Feature5 records
Hilab partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- Macau GovernmentminorHilab won the Macau Government's innovation and entrepreneurship competition (June edition) and is seeking expansion into the Chinese market, with Macau's Chief Executive supporting financial and commercial services between China and Portuguese/Spanish-speaking countries. The Macau government plans to invest 18.1 billion patacas in a science and technology research park expected to be completed by 2029.
Scale indicators4 records
Recent moves7 records
Expansion highlights5 records
Hilab competitors and assessment
Company assessmentEmerging players
- Wondfo: Wondfo is a Chinese POC diagnostics company with compact immunology and chemistry analyzers targeting global emerging markets, overlapping with Hilab's pharmacy and occupational health channels.
Broad incumbents
- Abbott (i-STAT / Point-of-Care): Abbott's i-STAT and broader POC diagnostics franchise competes directly with Hilab's portable analyzers in hospitals, urgent care, and occupational health, with far greater global reach and installed base.
- Roche Diagnostics: Roche's cobas Liat and broader POC/central lab portfolio competes with Hilab Flow, Volt, and Molecular across hospital and pharmacy channels globally, with deep clinical evidence and distribution.
- Cepheid (Danaher): Cepheid's GeneXpert molecular POC system is the closest direct competitor to Hilab Molecular, particularly for decentralized RT-PCR-style testing in clinics and public health settings.
- QuidelOrtho: QuidelOrtho's Sofia and Triage POC immunoassay systems overlap directly with Hilab Flow's immunochromatography and fluorescence menu across pharmacy and clinical settings.
- Siemens Healthineers: Siemens' epoc and RAPIDPoint POC blood gas/chemistry analyzers overlap with Hilab Volt and broader hospital POC menus, with significantly larger sales infrastructure.
- Mindray: Mindray's broad in-vitro diagnostics and POC portfolio across hematology, chemistry, and immunoassay competes with Hilab's multi-device offering, especially relevant as Hilab eyes China expansion.
Direct peers
- Nova Biomedical: Nova's StatStrip and Prime Plus compact blood gas/chemistry analyzers are highly comparable to Hilab Volt in form factor and clinical use cases for point-of-care hospital testing.
- SD Biosensor: SD Biosensor's STANDARD F and iChroma immunochromatography/fluorescence POC systems overlap with Hilab Flow, especially across emerging markets and pharmacy/occupational channels.
- EKF Diagnostics: EKF's QuikRead and Hemo Control compact POC hematology and chemistry analyzers are highly comparable to Hilab Lens and Volt in miniaturization and decentralized clinical use cases.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks5 records
Key highlights7 records
Customer concentration
Hilab social profiles
Digital presenceHilab compliance and trust
Trust signalCompliance3 records
Hilab financial estimates
Financial estimateRevenue estimate
Valuation estimate
Hilab leadership team
Management profileNumber of profiles
Profiles4 records
Hilab funding detail
Funding detailFunding overview
Funding rounds6 records
Investors11 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Hilab M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Hilab
What does Hilab do?
Hilab develops and manufactures ultra-compact point-of-care diagnostic devices (Hilab Lens, Flow, Volt, Molecular) that function as mini connected laboratories, paired with a cloud-based AI diagnostic platform that processes health data and delivers results in real time. The portfolio covers approximately 85% of the most requested medical examinations and is sold primarily to healthcare providers, laboratories, hospitals, pharmacies, occupational health programs, and public health systems in Brazil.
Is Hilab a public or private company?
Hilab is a private company. It is classified as venture growth investor backed and is currently operating.
When was Hilab founded?
Hilab was founded in 2004. It employs 101 to 250 people.
Where is Hilab based?
Hilab is headquartered in Curitiba, Brazil, in the Latin America region.
How does Hilab make money?
Three revenue lines are on record. Point-of-Care Diagnostic Devices are the primary driver. The others are diagnostic Testing Services (Per-Test) and enterprise and Institutional Solutions.
Who are Hilab's main competitors?
Wondfo is listed as an emerging player. Broad incumbents are Abbott (i-STAT / Point-of-Care), Roche Diagnostics, Cepheid (Danaher), QuidelOrtho, Siemens Healthineers and Mindray. Direct peers are Nova Biomedical, SD Biosensor and EKF Diagnostics.
Does Hilab have an API?
No public API is recorded for Hilab.
What industry is Hilab in?
Hilab's product category is Point-of-Care Diagnostic Devices. Its primary akta.pro industry code is HLACALAG, AI Orchestration & Imaging Analytics Platforms (Model Management/Triage), with a secondary code of HLACABAM, Imaging & Diagnostic Interoperability (DICOM exchange, image sharing, VNA connectivity). Its NAICS code is 3345 and its SIC code is 3841.